Objective: HIV-infected individuals are at increased risk for myocardial infarction. Given observations that cytomegalovirus (CMV) infection, CMV-specific T cells, and CX3CR1 have each been associated with atherosclerosis, we hypothesized that CMVinduced T-cell immunopathology could contribute to HIV-associated atherosclerosis.
Introduction
Individuals infected with HIV have higher rates of atherosclerosis than those who are not HIV-infected, even after controlling for traditional risk factors [1, 2] . Previous studies have associated such higher rates with both the use of combination antiretroviral therapy [3] [4] [5] and with higher levels of T-cell activation [1, 6] . The latter finding is particularly interesting because infiltrates of activated T cells also dominate early atherosclerotic lesions in the absence of HIV infection [7] .
The presence of activated T cells within atheromatous lesions implies the presence of a specific antigenic stimulation. Although the cause of such stimulation remains unclear, it is intriguing that, in HIV-infected patients, cytomegalovirus (CMV) infection can not only induce a large fraction of antigen-specific T cells but is also associated with a higher frequency of subclinical atherosclerosis [8] . This juxtaposition suggests a potential role for CMV-specific immunity in the pathogenesis of HIV-associated atherogenesis.
Indeed, CMV is a 'nontraditional' risk factor in atherogenesis and has been implicated in the pathogenesis of atherosclerosis mainly because of its ability to activate endothelial cells, the first and perhaps most important step in the development of the atherosclerosis [9] . In immunosuppressed patients, clinical studies suggest a direct relationship between CMV infection and atheroma. This seems particularly true in the setting of cardiac allograft recipients [10] in which treatment with anti-CMV therapy is associated with a reduced risk of transplantation-associated arteriosclerosis.
The continuous immigration and infiltration of activated macrophages and T cells into and within atherosclerotic lesions are prominent features in both human and experimental atherosclerotic disease. Among chemokine receptors that mediate the tissue migration of T cells, polymorphisms in CX3CR1 (encoding the receptor for CX3CL1 or fractalkine) have been previously associated with coronary artery disease in human [11] . Interestingly, CMV-specific CD4 þ T cells have themselves been shown to induce CX3CL1 in endothelial cells [12] .
Given the above observations that CMV infection, CMV-specific T cells, and CX3CR1 have each been associated with atherosclerosis, we hypothesized that, in the setting of HIV infection, CMV co-infection might enhance the expansion of CMV-specific T cells expressing CX3CR1, induce endothelial cells to produce CX3CL1, and drive the migration of CX3CR1 þ T cells into the arterial wall, promoting a chronic inflammatory process that culminates in atherosclerosis. The following studies provide compelling data in support of this hypothesis.
Methods
Populations studied HIV-infected individuals were recruited from an ongoing clinic-based cohort [Study of the Consequences of Protease Inhibitors Era (SCOPE)] based at the University of California San Francisco (UCSF), San Francisco, California, USA. Carotid intima-media thickness (IMT) measurements were available for 29 previously published individuals [8] . Control individuals were selected mainly from among individuals answering advertisements to participate in clinical studies who were of similar age and sex to the HIV-infected participants. The UCSF Committee on Human Research approved the study and all individuals provided written informed consent (see also Supplemental Methods for complete details, http://links.lww.com/QAD/A208).
Carotid intima-media thickness measurements
Carotid IMT was measured by high-resolution ultrasound, as described previously [1] . Briefly, carotid IMT was measured in 12 predefined segments (six segments per side) using the standardized protocol of the Atherosclerosis Risk in Communities (ARIC) study, which includes measurements of the near and far wall of the common carotid, the carotid bifurcation, and the internal carotid [13] . Measurement reproducibility in our laboratory has been described previously and the intraclass correlation coefficient is greater than 0.9 [1] . Baseline carotid IMT measurements were obtained within 1 month of the immunophenotyping analysis. IMT progression was calculated as the mean IMT at follow up -mean IMT at baseline/duration of follow-up (in years).
Flow cytometry
Panels of antibodies used for phenotypic detection and intracellular cytokine detection are described in Table S1 (http://links.lww.com/QAD/A208). Fluorescence Activated Cell Sorter analysis was performed on a four-laser BD LSR-II flow cytometer (Becton Dickinson, San Jose, California, USA) and data were analyzed with FlowJo software v8-6 (Treestar Inc., Ashland, Oregon, USA). The strategy used to gate the different subsets of peripheral blood mononuclear cells (PBMCs) is shown in Figure S1 (http://links.lww.com/QAD/A208).
ELISA
Soluble fractalkine (CX3CL1) was detected in culture supernatants with a commercially available ELISA detection kit (R&D Systems Inc., Minneapolis, Minnesota, USA).
In-vitro cytomegalovirus infection VR1814, an endothelial cell-tropic clinical strain of CMV isolated from the cervix, was adapted for growth in human artery endothelial cells (HAECs; Lonza Inc., Allendale, New Jersey, USA) [14] . CMV infection was identified by production of its characteristic cytopathic 806 AIDS 2012, Vol 26 No 7 effects (CPEs) and immunostaining for CMV immediate early proteins (Millipore, Billerica, Massachusetts, USA).
Co-cultures of peripheral blood mononuclear cell or subset populations with human artery endothelial cell monolayers
Cocultures were set up with confluent primary HAEC monolayers overlaid with either 10 6 PBMC or CD4 þ T cells overnight. CMV infection of HAECs was assessed when more than 50% of the cells showed CPE. The CD4 þ T cells were depleted from PBMCs with the use of a positive selection MidiMACS system and LD immunomagnetic column (Miltenyi Biotech, Cambridge, Massachusetts, USA).
Neutralization assays
Blocking antibodies specific for tumor necrosis factor (TNF)a (Becton Dickinson) and interferon (IFN)g (Becton Dickinson) were added at the time of cocultivation of PBMC with CMV-infected HAEC. Purified mouse immunoglobulin G1 and IgG2aK antibodies were used as isotype controls (Becton Dickinson). The manufacturer's recommended concentrations were used for neutralization assays.
Transendothelial migration assay HAEC were seeded on the membrane of transwell inserts (12 mm diameter, 3 mm pore size; Corning Life Sciences, Union City, California, USA) to form polarized monolayers. The purity of HAEC was verified by immunofluorescence staining with rabbit antihuman von Willebrand Factor (Abcam, Cambridge, Massachusetts, USA). The formation of polarized monolayers was monitored by staining with mouse antihuman VEcadherin (R&D systems). CD4 þ T cells were enriched from PBMC populations using a negative selection MidiMACS system and LS immunomagnetic column (Miltenyi Biotech). Recombinant human CX3CL1 (R&D Systems) or control media were loaded into lower well chambers. CD4 þ T cells (10 5 ) were placed into the upper chamber well inserts for a cell-migration period of 4 h. For each assay, three replicate wells were set up.
Immunohistochemistry assay
Specimens of coronary arteries were collected from autopsies (NCI AIDS and Cancer Specimen Resource, UCSF), fixed in buffered formalin, and embedded in paraffin. Sections were classified into minimal atherosclerotic and diffuse atherosclerotic coronary arteries. EDTA buffer was used for antigen retrieval. Primary antibodies used were antihuman CD4 mouse monoclonal (clone 1F6), antihuman CD3 mouse monoclonal (clone PS1), or antihuman CX3CR1 rabbit polyclonal (Thermoscientific, Waltham, Massachusetts, USA). Detection of primary antibodies was performed with horseradish peroxidase polymer (DAKO Envision kit;
Dako North America, Inc., Carpinteria, California, USA)-conjugated antibodies and developed with 3,3 0diaminobenzidine. Counterstains were done with Mayer's hematoxylin.
Statistical analyses
Exact nonparametric two-tailed tests were used. The nonparametric Mann-Whitney U-test was used to compare continuous variables. The Fisher's exact test was used to compare dichotomous variables. The Spearman rank correlation test was used to determine correlations between variables, with r being the Spearman correlation coefficient. Statistical analysis was performed with GraphPad Prism 5.01 software (GraphPad Software Inc., La Jolla, California, USA). Multiple linear regression was used to assess the strength of association between pairs of variables while adjusting for confounders (e.g. age).
The P values of less than 0.05 were considered statistically significant. Table 1 outlines the characteristics of the 29 HIVinfected individuals and 48 HIV-uninfected controls.
Results

Characteristics of individuals studied
HIV-infected individuals were classified into two groups with 'high' or 'low' carotid artery IMT, that is, above or below 1 mm in thickness (the mean value of carotid IMT in HIV-positive individuals) [1] . The mean age of the HIV-infected individuals was 47.3 years and 27 (93.1%) were male. Sixteen (55.2%) were receiving antiretroviral therapy that, in each case, included a protease inhibitor. The median CD4 þ T-cell count was 514 cells/ml. Most (55.2%) had undetectable HIV-RNA levels (<75 copies/ml). Among HIV-positive individuals with detectable viral load, the mean (AESD) and median (range) value of HIV-RNA levels were of 55 521 (AE133 341) and 8871 copies/ml (735-470 066). Compared to controls, HIV-infected individuals did not show any statistical differences in terms of age, sex, tobacco use, hypertension, cholesterol treatment, or BMI.
The mean IMT measurement at baseline in HIV-positive high IMT and HIV-positive low IMT individuals was 1.32 (AE0.4) and 0.73 mm (AE0.11), respectively. The mean IMT progression in these two groups was 0.1 (AE0.15) and 0.05 mm/year (AE0.15) (P ¼ 0.53), respectively. As compared to the HIV-positive low IMT group, members of the HIV-positive high IMT group were older (P ¼ 0.002), but did not show any other statistically significant differences in term of classical risk factors for coronary disease. However, individuals with high IMT tended to have a higher 10-year risk of coronary heart disease (calculated using the Framingham risk equation).
The frequency of CD4 R CX3CR1 R T cells correlates with intima-media thickness progression in HIV-infected individuals
We first investigated the expression of CX3CR1 on PBMCs in HIV-infected and HIV-uninfected individuals using multiparameter flow cytometry ( Fig. 1a ). Among HIV-uninfected adults, CX3CR1 was found to be expressed on 9.2% (AE7.2) of CD4 þ T cells, 35.7% (AE17.6) of CD8 þ T cells, 86.2% (AE9.5) of CD16 þ cells [natural killer (NK) cells], 98.8% (AE1.6) of CD14 þ (monocytes), and 2% (AE1) of CD19 þ cells (B cells). Among HIV-infected individuals, 13.8% (AE14.7) of CD4 þ T cells, 40.2% (AE18.1) of CD8 þ T cells, 86.6% (AE8.7) of NK cells, 99.3% (AE1) of monocytes, and 3.4% (AE3) of B cells expressed CX3CR1. The percentage of cells expressing CX3CR1 did not differ significantly between HIV-infected and HIV-uninfected individuals for any of these subsets of PBMCs. However, HIVinfected individuals tended to have a higher percentage of CD4 þ CX3CR1 þ T cells than did those who were HIVuninfected (P ¼ 0.07). The expression of CX3CR1 on CD4 þ T cells was not associated with the HIV viral load ( Figure S2A , http://links.lww.com/QAD/A208).
Measurement of carotid IMT assesses the presence of subclinical atherosclerosis and has been strongly correlated with coronary atherosclerosis [15] . Interestingly, the percentage of CD4 þ T cells expressing CX3CR1 in HIVpositive low IMT individuals was 7.9% (AE7.4) and did not differ from that observed in HIV-uninfected individuals (P ¼ 0.10) ( Fig. 1b) . By contrast, the percentage of CD4 þ T cells expressing CX3CR1 in HIV-positive high IMT individuals [21.1% (AE18.2)] was higher than that found in each of the former groups (P ¼ 0.0005 relative to HIV-uninfected individuals and P ¼ 0.004 relative to HIV-positive low IMT individuals) ( Fig. 1b ). Thus, in HIV-infected individuals, a high frequency of CD4 þ T cells expressing CX3CR1 was associated with a high IMT.
The HIV viral load did not significantly differ between HIV-positive low IMT and HIV-positive high IMT individuals ( Figure S2B , http://links.lww.com/ QAD/A208). Baseline IMT measurements were also similar in individuals whether or not they were being treated with a protease inhibitor ( Figure S2C , http:// links.lww.com/QAD/A208).
To further characterize the link between the frequency of CD4 þ CX3CR1 þ T cells in the peripheral blood and measurements of carotid artery IMT in HIV-infected individuals, we analyzed the relationship between these two parameters on a longitudinal basis. An individual with a high frequency of CD4 þ CX3CR1 þ T cells (3133) was found to have a higher IMT measurement at baseline than did an individual with a low frequency of CD4 þ CX3CR1 þ T cells (2074); individual 3133 also showed faster progression of IMT over time (Fig. 1c) .
These observations were extended to a larger group of individuals to find that the frequency of CD4 þ CX3CR1 þ T cells was correlated with IMT measurements at baseline (r ¼ 0.52, P ¼ 0.048 after adjustment for age) ( Fig. 1d ) and with IMT progression over time (r ¼ 0.43, P ¼ 0.038 after adjustment for age) ( Fig. 1e ) in HIV-infected individuals.
cells are antigen-primed and activated T cells producing high levels of TNFa and IFNg upon T-cell receptor stimulation
Multiparameter immunophenotyping was carried out on CD4 þ T cells to define the subsets of cells expressing CX3CR1, focusing on CD27 (a costimulatory receptor involved in generation and long-term maintenance of 808 AIDS 2012, Vol 26 No 7 T-cell immunity) [16] , CD45RA (a marker associated with the definition of naive and memory T cells) [17] , and human leukocyte antigens-DR (HLA-DR) (a marker of Tcell activation) [18] . CD4 þ T cells that expressed CX3CR1 were predominantly CD45RA À CD27 À , a phenotype of antigen-primed CD4 þ T cells. These cells were also found to be CD57 þ , CCR7 À , and programmed death (PD)-1 þ (Figure S3 , http://links.lww.com/QAD/ A208). In contrast, CD4 þ T cells that did not express CX3CR1 were mostly CD45RA þ/À CD27 þ . Both of these subpopulations had high frequencies of cells that were HLA-DR þ (Fig. 2a) . In a larger group of individuals, the expression of CX3CR1 on CD4 þ T cells was found to correlate with the lack of expression of CD45RA and CD27 in both HIV-uninfected [r ¼ 0.53, 95% confidence interval (CI) 0.28-0.71, P ¼ 0.0001] and in HIV-infected individuals (r ¼ 0.44, 95% CI 0.08-0.70, P ¼ 0.01) ( Fig. 2b, upper panel) . The expression of CX3CR1 on the surface of the CD4 þ T cells was also correlated with the expression of HLA-DR in both groups (HIV-negative:
r ¼ 0.46, 95% CI 0.19-0.66, P ¼ 0.001) (HIV-positive: r ¼ 0.70, 95% CI 0.44-0.85, P < 0.0001) ( Fig. 2b, lower  panel) . Consistent with the phenotype of antigen-primed cells, CD4 þ T cells that expressed CX3CR1 showed the functional properties of pro-inflammatory T cells: upon T-cell receptor activation by CD3/CD28 costimulation in vitro, CD4 þ CX3CR1 þ T cells produced significantly more TNFa (17.3 AE 11.8 vs. 8 AE 5.7%, P ¼ 0.007) and IFNg (14 AE 19 vs. 1.6 AE 1.7%, P ¼ 0.002) than did CD4 þ CX3CR1 À T cells ( Fig. 2c and d) .
CD4 R CX3CR1 R T cells are mostly CMV-specific CD4 R T cells and CD4 R T-cell response to CMV antigen induces endothelial cell production of CX3CL1, the cognate chemokine ligand of CX3CR1 CMV is a nontraditional risk factor for atheroma that may be particularly important in the context of HIV infection wherein the prevalence of CMV infection is high [19] , subclinical replication of CMV is frequent [20] , and CMV-specific T-cell responses are associated with increased IMT [8] . To determine whether the CD4 þ CX3 CX3 CR1 þ T-cell population in HIV-infected individuals might harbor a high frequency of CMV-specific cells, these cells were tested for CMV specificity using a cytokine production assay. In HIV-positive individuals, the percentage of CD4 R T cells producing TNFa and IFNg upon stimulation with CMV pp65 peptide pools was 2.9% (AE3) and 3.7% (AE3.4), respectively ( Figure S4 , http:// links.lww.com/QAD/A208). Interestingly, CD4 R T cells that expressed CX3CR1 produced significantly more TNFa (2.2 AE 2.3 vs. 0.7 AE 0.8%, P ¼ 0.005) and IFNg (2.9 AE 2.9 vs. 0.8 AE 0.7%, P ¼ 0.009) than did CD4 þ CX3 CR1 À T cells. Thus, based on the TNFa and IFNg production, more than 75% of the CMV-specific CD4 þ T cells expressed CX3CR1 ( Fig. 3a and b) .
We then tested the possibility that CMV infection of HAECs might induce the production of CX3CL1, the cognate chemokine ligand of CX3CR1, and thus facilitate the migration of CD4 þ CX3CR1 þ T cells through the arterial wall. Limited CX3CL1 production was detected (by ELISA) in the supernatant of uninfected HAEC culture (HAEC CMVÀ ) and there was only a slight increase after infection of endothelial cells by CMV (HAEC CMVþ ). When PBMCs from CMV-infected individuals were cocultured with uninfected endothelial cells (HAEC CMVÀ PBMCs), there was no increase in the level of CX3CL1 in the supernatant. However, when such PBMCs were cocultured with CMV-infected endothelial cells (HAEC CMVþ PBMCs), there was a dramatic increase in the level of CX3CL1 (Fig. 3c) . Interestingly, when CD4 þ T-cell-depleted PBMCs were cocultured with CMV-infected HAEC, the production of CX3CL1 was significantly reduced (mean reduction of 33 þ 24%, P ¼ 0.04) (Fig. 3d) . These results, reproducible across all four donors tested, demonstrate that CMV-specific CD4 þ T cells can induce CX3CL1 expression in CMVinfected endothelial cells. The identification of the CD4 þ T-cell subset that induces CX3CL1 in endothelial cells and the ability of CD4 þ CX3CR1 þ T cells to produce high levels of TNFa and IFNg suggested that these cytokines may play a role in the induction of CX3CL1 in endothelial cells. Indeed, a marked reduction in CX3CL1 levels was observed when CMV-infected HAECs, cocultured with PBMCs, were treated with neutralizing antibodies against either TNFa or IFNg (Fig. 3d) . Thus, we conclude that CD4 þ T-cell-derived TNFa and IFNg are likely to be the dominant soluble factors induce the production of CX3CL1 by endothelial cells. replicate pooled samples were used to calculate the mean transmigrated cell number per milliliter. As shown in Fig. 4a , CX3CL1 induced the transendothelial migration of CD4 þ T cells in a concentration-dependent manner, with the highest numbers (48 900 AE 7900 cells/ml, 16.7 AE 2.6% of the CD4 þ CX3CR1 þ T cells loaded) observed at a concentration of 200 ng/ml and the lowest (5000 AE 1000 cells/ml, 1.6 AE 0.4% of the CD4 þ CX3CR1 þ T cells loaded) with the chemokine-negative control.
To extend these findings to conditions that might exist in vivo, we next asked whether CD4 þ CX3CR1 þ T cells are localized within the wall of the coronary artery in HIVpositive individuals with atherosclerosis. Immunohistochemical analysis of the coronary arterial wall in different developmental stages of atherosclerotic plaques showed expression of CD3, CD4, and CX3CR1 within lesions at an early stage of the disease (Fig. 4b) . Immunoreactivity for all three markers was located in the external tunic of the artery in proximity to the atherosclerotic lesions and was mostly confined to the lumen (CX3CR1), in the wall (CD4), or around the vessels running in the adventitia (CD3). Except for the detection of CX3CR1, no immunoreactivity was observed in atherosclerotic lesions examined at late stage of disease ( Figure S5 , http:// links.lww.com/QAD/A208).
Discussion
In this study, we show that HIV-associated atherosclerosis is correlated with a high frequency of peripheral blood CD4 þ T cells expressing CX3CR1, the chemokine receptor of CX3CL1 (fractalkine); many of these cells are CMV-specific and CMV can drive the migration of them through the arterial wall by enhancing the production of CX3CL1 by HAECs. Given prior data from our group that HIV infection is associated with expansion of CMVspecific T cells and that CMV-specific T cells are associated with atherosclerosis in HIV-infected adults [8, 21] , these data support a conceptual model in which the immune dysfunction associated with HIV infection is associated with, first, an increased frequency of circulating CD4 þ CX3CR1 þ T cells, many of which are specific for CMV; second, an increased presentation of CMV by endothelial cells to T cells; third, an increased production of TNFa and IFNg by antigen-stimulated CD4 þ CX3CR1 þ T cells, driving the endothelial production of the ligand CX3CL1; and, fourth, the transendothelial migration of pro-inflammatory CD4 þ T cells (see Figure S6 for a schematic model depicting these events, http://links.lww.com/QAD/A208).
Consistent with the potential pro-atherogenic role for the CD4 þ T cells expressing CX3CR1, CD4 þ CX3CR1 þ T cells shared the memory effector phenotype of T cells found in the atherosclerotic plaque [22] . In addition, by being mostly CCR7 À (Figure S3 , http://links.lww.com/ QAD/A208), CD4 þ CX3CR1 þ T cells also have the ability to accumulate in inflammatory tissue [23] . Finally, mice deficient in the inhibitory molecules programmed death-ligand 1 (PD-L1) and PD-L2 have been shown to have larger atheroma plaques with massive infiltration of CD4 þ T cells [24] . These data indicate that these cells might be controlled by PD-1 in atherosclerosis and we here observed that CD4 þ CX3CR1 þ T cells mostly expressed PD-1 ( Figure S3 , http://links.lww.com/QAD/A208).
As CD4 þ T cells expressing CX3CR1 þ are antigenprimed and activated, the heightened expression of CX3CR1 in HIV disease may be a consequence of the immune activation that is the hallmark of HIV disease progression [18] . However, because CD4 þ CX3CR1 þ T cells are mainly CMV-specific, the higher level of circulating CD4 þ CX3CR1 þ T cells may also be the simple consequence of greater exposure to CMV antigen during the course of HIV disease. Accordingly, we observed that CD4 þ CX3CR1 þ T cells predominantly expressed CD57 þ , an antigen-primed marker highly expressed on CMV-specific T cells [25, 26] . In sum, because they are both CX3CR1 þ and pro-inflammatory, CMV-specific CD4 þ T cells are ideally suited to migrate through the endothelium and to play a pro-atherogenic role in the arterial wall.
We determined how a high level of CD4 þ CX3CR1 þ T cells in blood could be mechanistically linked to atherosclerosis by showing that CMV-induced T-cell immunopathology can drive the migration of these cells through the wall artery. Here, we largely confirmed what was previously described by Bolovan-Fritts et al. [12] that the production of TNFa and IFNg by CMV-specific CD4 þ T cells induces the production of CX3CL1 by endothelial cells. We have also extended this previous study to show that the CD4 þ CX3CR1 þ T cells targeted by CX3CL1 are correlated with HIV-associated atherosclerosis in vivo, comprise the majority of the CMVspecific CD4 þ T cells, produce high levels of TNFa and IFNg (two key pro-inflammatory cytokines involved in atherosclerosis [7, 9, 27] ), and can migrate through the AECs. Our study accordingly offers a novel and comprehensive picture of how CMV-induced T-cell immunopathology may be involved in the pathogenesis of atherosclerosis. However, it is important to note that, given the rarity of the material, we have only studied two sets of coronary arteries from one donor by immunohistochemistry: one set at an early stage of atherosclerosis and another at a later stage. More samples need to be studied in the future, especially at a pre-atherosclerotic stage, so that the current observations can be confirmed and extended.
Interestingly, we observed that almost all monocytes, the most important players of atherosclerosis pathogenesis, expressed CX3CR1. It is accordingly possible that endothelial production of CX3CL1 may also promote pro-atherogenic inflammatory events by affecting the trafficking of monocytes. These observations suggest that CX3CL1 and its cognate receptor, CX3CR1, are part of a chemokine-based positive feedback circuit involved in atherosclerosis, one that may represent an attractive therapeutic target. The ongoing inflammatory process in the arterial wall would presumably be most pronounced in those with the highest frequency of CMV-specific T cells, as has been observed in the context of HIV infection [21] . If so, then treatment of CMV infection (e.g. with valganciclovir) [28] would be an attractive therapeutic option.
In summary, our data suggest that CD4 þ T cells expressing CX3CR1 play a key role in the pathogenesis of HIVassociated atherosclerosis, one that is proximally driven by CMV infection of endothelial cells. Elucidation of this mechanism provides support for treatment interventions (e.g., inhibition of CMV replication and/or of CX3CR1/ CX3CL1 interactions) that might ultimately slow the pace of atherosclerosis in vivo. Given the prevalence of CMV infection and of T-cell activation in the aging individuals who are not infected with HIV [29] , such interventions may prove beneficial to a much larger patient population than just those with HIV alone. 
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